Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal to IL-10RB - BSA and Azide free (Detector)
- Suitable for: Sandwich ELISA
- Reacts with: Human
Product nameAnti-IL-10RB antibody - BSA and Azide free (Detector)
See all IL-10RB primary antibodies
DescriptionRabbit monoclonal to IL-10RB - BSA and Azide free (Detector)
Tested applicationsSuitable for: Sandwich ELISAmore details
Species reactivityReacts with: Human
ab259506 is a BSA and Azide Free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Human IL-10RB. The recommended pair for sandwich ELISA is:
Capture: ab259505, Human IL-10RB Capture Antibody (unconjugated)
Detector: ab259506, Human IL-10RB Detector Antibody (unconjugated)
The reference range value is 31.25 - 2000 pg/ml.
The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is a recombinant monoclonal antibody, which offers several advantages including:
-High batch-to-batch consistency and reproducibility
-Improved sensitivity and specificity
-Long-term security of supply
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C.
Concentration information loading...
sELISA pair antibody
Our Abpromise guarantee covers the use of ab259506 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit monoclonal to IL-10RB - BSA and Azide free (Capture) (ab259505).|
FunctionShared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IL29.
Involvement in diseaseDefects in IL10RB are the cause of inflammatory bowel disease type 25 (IBD25) [MIM:612567]. It is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
Sequence similaritiesBelongs to the type II cytokine receptor family.
Contains 2 fibronectin type-III domains.
- Information by UniProt
- CDw210b antibody
- CRF2 4 antibody
- CRF2-4 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab259506 has not yet been referenced specifically in any publications.